Brainstorm Cell Therapeutics (BCLI) AI Stock Analysis

• Market Cap: $6.59M
• Dividend Yield: N/A
• Average Volume (3M): 414.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.65
• Revenue Growth: N/A
• EPS Growth: 62.35%
• Country: US
• Employees: 27
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 9,838,859
• 10 Day Avg. Volume: 223,592
• 30 Day Avg. Volume: 414,610
• PEG Ratio: -0.05
• Price to Book (P/B): -1.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.54
• Enterprise Value/Market Cap: 1.81
• Enterprise Value/Revenue: 17.39
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.22
• 1Y Price Target: $6.60
• Price Target Upside: 885.07% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

Brainstorm Cell Therapeutics' stock score is significantly impacted by its financial performance challenges, including ongoing losses and negative cash flows. While there are strategic advancements and partnerships aimed at derisking the regulatory pathway, the company's valuation and technical indicators reflect a bearish outlook. Investors should be cautious due to financial constraints and skepticism regarding the efficacy of its lead treatment, NurOwn.

Positive Factors

Manufacturing and Collaboration

The strategic collaboration with Minaris Advanced Therapies enhances US-based manufacturing capabilities and brings the scalability needed for NurOwn's complex autologous cell therapy.

Regulatory Progress

FDA clearance for the upcoming P3b (ENDURANCE) study in amyotrophic lateral sclerosis (ALS) announced, positioning BrainStorm to acquire funds for the trial, including non-dilutive sources like a $15M grant under review.

Therapeutic Efficacy

BrainStorm announced new survival data from the Expanded Access Program for NurOwn cell therapy, showing that 90% of patients survived more than five years, compared to the average life expectancy for ALS patients of 2-5 years.

Negative Factors

Financial Challenges

BrainStorm reported a net loss of ($2.9M) and ended the period with $1.8M in cash on the balance sheet.

Market and Capital Needs

Additional capital is required to fund the P3b study, and the delisting makes this more challenging.

Risk of Dilution

The company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.

Brainstorm Cell Therapeutics Business Overview & Revenue Model

Company Description

Brainstorm Cell Therapeutics (BCLI) is a biotechnology company focused on the development of innovative cellular therapies for the treatment of neurodegenerative diseases. Operating primarily in the biotechnology sector, the company's core product is NurOwn, an autologous cellular therapy that utilizes mesenchymal stem cells to deliver neurotrophic factors directly to the site of damage in the nervous system. Brainstorm is committed to providing transformative solutions that improve patient outcomes and address unmet medical needs in conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

How the Company Makes Money

Brainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.

Brainstorm Cell Therapeutics Financial Statement Overview

Summary

Brainstorm Cell Therapeutics faces significant financial challenges, with ongoing losses and negative cash flows. Despite a slight improvement in equity, the company's financial stability is still at risk, requiring strategic changes to improve revenue and cash flow.

Income Statement

Brainstorm Cell Therapeutics shows a significant net loss for multiple years with minimal revenue in 2024. The gross profit margin is 100% due to its small revenue covering costs, but net profit margins remain negative. The revenue growth rate is not meaningful due to zero revenue in previous years. Continued negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The company has a fluctuating equity position, currently positive but previously negative. The debt-to-equity ratio is relatively low at 0.87, indicating some financial stability. However, the equity ratio is modest due to past negative equity, reflecting potential risk.

Cash Flow

Operating cash flow remains negative, indicating insufficient cash generation from operations. Free cash flow is also negative, with a significant growth in free cash flow loss compared to past years. The operating cash flow to net income ratio is not meaningful due to consistent net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	849.00K	0.00	0.00	0.00	0.00
Gross Profit	849.00K	-265.00K	-285.00K	-260.00K	-219.00K
EBITDA	0.00	-16.93M	-23.99M	-24.28M	-31.46M
Net Income	11.62M	-17.19M	-24.28M	-24.46M	-31.81M
Balance Sheet
Total Assets	1.83M	4.21M	8.45M	29.28M	51.26M
Cash, Cash Equivalents and Short-Term Investments	187.00K	1.30M	2.98M	22.09M	41.94M
Total Debt	720.00K	672.00K	4.09M	5.08M	7.22M
Total Liabilities	9.60M	9.07M	11.47M	9.94M	15.79M
Stockholders Equity	-7.76M	-4.86M	-3.02M	19.34M	35.46M
Cash Flow
Free Cash Flow	-9.09M	-20.48K	-19.35M	-26.59M	-35.57M
Operating Cash Flow	-9.09M	-20.46M	-19.32M	-26.27M	-35.19M
Investing Cash Flow	12.00K	2.19M	998.00K	323.00K	-4.45M
Financing Cash Flow	7.97M	18.98M	238.00K	6.97M	76.94M

Brainstorm Cell Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Negative. The current price of 0.67 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.07, and below the 200-day MA of 1.47, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 27.18 is Positive, neither overbought nor oversold. The STOCH value of 32.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCLI.

Brainstorm Cell Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	0.50	-65.61%	2.47%	15.28%	1.44%
LYRA	46 Neutral	$10.52M	―	-195.46%	―	-29.46%	2.71%
APM	41 Neutral	$9.79M	49.73	-18.56%	―	-100.00%	―
BCLI	40 Underperform	$6.59M	―	234.90%	―	―	62.35%
GTBP	34 Underperform	$5.70M	―	-538.87%	―	―	-26.02%